COMMUNIQUÉS West-GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences
08/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 08, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies London Healthcare Conference on Thursday, [...]
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio
08/11/2018
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio Upfront payment of US$15m Up to US$80m of development milestone payments Mid teen percentage profit share [...]
Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference
08/11/2018
EWING, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare [...]
Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
08/11/2018
Research Found Exosomes Increased Exercise Capabilities and Muscle Activity in a Mouse Model of Duchenne Muscular Dystrophy LOS ANGELES, Nov. 08, 2018 (GLOBE NEWSWIRE) -- During the Action Duchenne International [...]
Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)
08/11/2018
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Chimerix Announces Third Quarter 2018 Financial Results
08/11/2018
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, [...]
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
08/11/2018
Results to be presented show a significant reduction of Lp(a) levels, favorable safety and tolerability profile BOSTON and CARLSBAD, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an [...]
Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
08/11/2018
CDX-6114 meets safety and tolerability endpoints REDWOOD CITY, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces top-line results from its Phase 1a [...]
Canada House Clinics Partners with Peak Pharma Solutions for Patient Growth
08/11/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Canada House Clinics, the clinic division of Canada House Wellness Group Inc (“Canada House [...]
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2018
08/11/2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV [...]
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
08/11/2018
ALPHARETTA, Ga., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update
08/11/2018
ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate SAN FRANCISCO, Nov. 08 [...]
ContraFect Announces Third Quarter 2018 Financial Results
08/11/2018
YONKERS, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]
Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update
08/11/2018
ELX-02 has been granted an orphan drug designation by the European Medicines Agency (EMA) for Cystic Fibrosis Advancing several investigational drug candidates from our library in IND enabling studies for rare inherited [...]
Recro Pharma to Participate in Upcoming Investor Conferences
08/11/2018
MALVERN, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today [...]
Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring
08/11/2018
– $70.0 Million of Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 – – Company to host conference call and webcast at 8:00am EST – CHESTERBROOK, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Trevena, [...]
Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
08/11/2018
DEVON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]
Zealand hosts conference call on November 15 at 4 pm CET (10 am EST) to present third quarter results for 2018
08/11/2018
Press Release - No. 22 / 2018 Zealand hosts conference call on November 15 at 4 pm CET (10 am EST) to present third quarter results for 2018 Copenhagen, November 8, 2018 - Zealand Pharma A/S ("Zealand") (CVR no. 20 04 [...]
Virbac : Declaration of the number of shares and voting rights as of October 2018, 31.
08/11/2018
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

Pages